Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.55 |
| ▸ | CTSL | P07711 | 6/20 | 0.54 |
| ▸ | CTSB | P07858 | 6/20 | 0.54 |
| ▸ | CTSS | P25774 | 3/20 | 0.54 |
| ▸ | CTSK | P43235 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | TYR | P14679 | 1/20 | 0.52 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5689118 | 1.00 | TACR1 (0.55) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL17039822 | 1.00 | TACR1 (0.55) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL8208600 | 0.95 | CTSB (0.56) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL11301054 | 0.90 | CASP1 (0.50) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL10753165 | 0.90 | CTSL (0.51) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL22657970 | 0.89 | CASP1 (0.60) | CASP1 | |
| SCHEMBL22657972 | 0.89 | CASP1 (0.60) | CASP1 | |
| SCHEMBL356447 | 0.89 | CTSK (0.53) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL9044348 | 0.89 | ALDH1A1 (0.47) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL13715882 | 0.89 | CTSL (0.55) | CTSLCTSBCTSSCTSKCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2729443-B3 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2020-02-12 | — | — | EP | disclosed |
| EP-2870137-B1 | POLYMORPHS OF N-[(R)-1-[(S)-1-(4-AMINOMETHYL-BENZYLCARBAMOYL)-2-PHENYL-ETHYLCARBAMOYL]-2-(4-ETHOXY-PHENYL)-ETHYL]-BENZAMIDE HYDROCHLORIDE | KALVISTA PHARMACEUTICALS LTD (GB) | 2018-05-16 | — | — | EP | disclosed |
| US-9512065-B2 | Polymorphs of N-[(R)-1-[(S)-1-(4-aminomethyl-benzylcarbamoyl)-2-phenyl-ethylcarbamoyl]-2-(4-ethoxy-phenyl)-ethyl]-benzamide hydrochloride | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-12-06 | — | — | US | disclosed |
| US-9234000-B2 | Benzylamine derivatives as inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-01-12 | — | — | US | disclosed |
| EP-2729443-B1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2015-11-25 | — | — | EP | disclosed |
| US-20150225450-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2015-08-13 | — | — | US | disclosed |
| US-20150191421-A1 | POLYMORPHS OF N-[(R)-1-[(S)-1-(4-AMINOMETHYL-BENZYLCARBAMOYL)-2-PHENYL-ETHYLCARBAMOYL]-2-(4-ETHOXY-PHENYL)-ETHYL]-BENZAMIDE HYDROCHLORIDE | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2015-07-09 | — | — | US | disclosed |
| US-9051249-B2 | Benzylamine derivatives as inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2015-06-09 | — | — | US | disclosed |
| EP-2870137-A1 | POLYMORPHS OF N-[(R)-1 -[(S)-1-(4-AMINOMETHYL-BENZYLCARBAMOYL)-2-PHENYL-ETHYLCARBAMOY L]-2-(4-E THOXY-PHENYL)-ETHYL]-BENZAMIDE HYDROCHLORIDE | Kalvista Pharmaceuticals Limited (GB) | 2015-05-13 | — | — | EP | disclosed |
| US-20140213611-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2014-07-31 | — | — | US | disclosed |
| EP-2729443-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | Kalvista Pharmaceuticals Limited (GB) | 2014-05-14 | — | — | EP | disclosed |
| WO-2014006414-A1 | POLYMORPHS OF|N-[(R)-1 -[(S)-1-(4-AMINOMETHYL-BENZYLCARBAMOYL)-2-PHENYL-ETHYLCARBAMOY L]-2-(4-E|THOXY-PHENYL)-ETHYL]-BENZAMIDE HYDROCHLORIDE | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2014-01-09 | — | — | WO | disclosed |
| WO-2013005045-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2013-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191421-A1 | POLYMORPHS OF N-[(R)-1-[(S)-1-(4-AMINOMETHYL-BENZYLCARBAMOYL)-2-PHENYL-ETHYLCARBAMOYL]-2-(4-ETHOXY-PHENYL)-ETHYL]-BENZAMIDE HYDROCHLORIDE | SCN1A, SCN1B, BBC3 | TACR1 202/4885CTSL 1338/4885CTSB 1051/4885 |
| US-20150225450-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, BDKRB1 | TACR1 857/4885CTSL 276/4885CTSB 207/4885 |
| US-20140213611-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, BDKRB1 | TACR1 857/4885CTSL 276/4885CTSB 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.